convalescent plasma (Hospital de Infecciosas Francisco Javier Muniz)

Convalescent plasma (Hospital de Infecciosas Francisco Javier Muniz) is a passive immunotherapy treatment derived from the blood of individuals who have recovered from COVID-19. This plasma contains high titers of neutralizing antibodies specifically targeting the SARS-CoV-2 virus. When administered to infected patients, particularly those in critical condition, these antibodies bind to the viral spike protein, preventing the virus from entering host cells and facilitating its clearance by the immune system. The Hospital de Infecciosas Francisco Javier Muniz initiated a Phase 2 clinical trial to evaluate the efficacy of this treatment in reducing mortality and the length of stay in intensive care units for critically ill COVID-19 patients, including those requiring mechanical ventilation.

Other names

COVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasmaCCPconvalescent plasma-Hospital de Infecciosas Francisco Javier Muniz-COVID-19